Neurocrine sheds 200 Indiplon reps

Share this article:
Neurocrine Biosciences has laid off its entire 200-person sales force, the San Diego firm said. The decision follows Pfizer's ending of its marketing partnership with Neurocrine after the latter lost approval for insomnia drug Indiplon, and Pfizer lost US patent protection for Zoloft.

Neurocrine was then unable to acquire a product to keep the reps busy as it continues to seek FDA approval for Indiplon.

Neurocrine plans to meet with the FDA to finalize plans for the resubmission of each Indiplon NDA and to commercialize Indiplon quickly upon approval.
Neurocrine also said it is reviewing other possible future partnerships.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.